FibroBiologics, Inc. Common Stock (FBLG) is a publicly traded Healthcare sector company. As of May 21, 2026, FBLG trades at $1.06 with a market cap of $5.68M and a P/E ratio of -2.45. FBLG moved -4.17% today. Year to date, FBLG is -78.44%; over the trailing twelve months it is -94.25%. Its 52-week range spans $0.95 to $77.80. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces FBLG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FibroBiologics Achieves 3-Fold IL1B Reduction, 4-Fold IL10 Rise in Burn Study: Daily topical treatments with human dermal fibroblast spheroids over eight days in burn-injured mice eliminated the prominent red inflammatory border across multiple strains and both sexes. Biomarker analysis revealed a 3-fold reduction in IL1B, 4-fold increase in IL10 and downward trends in Col1a1, Col3a1, Mmp1a, Mmp8 and Acta2.
| Metric | Value |
|---|---|
| Price | $1.06 |
| Market Cap | $5.68M |
| P/E Ratio | -2.45 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $77.80 |
| 52-Week Low | $0.95 |
| Volume | 406 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-18.65M |
| Gross Margin | 0.00% |
3 analysts cover FBLG: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.